New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists. Issue 3 (8th September 2005)

• Record Type: Journal Article
• Authors: Kary, S; Worm, M; Audring, H; Huscher, D; Renelt, M; Sörensen, H; Ständer, E; Maaß, U; Lee, H; Sterry, W; Burmester, G-R
• Is Part Of: Annals of the rheumatic diseases. Volume 65:Issue 3(2006)
• Page Start: 405
• Page End: 407
• Publication Date: 2005-09-08
• Subjects: LEF, leflunomide -- MTX, methotrexate -- RA, rheumatoid arthritis -- TNFα, tumour necrosis factor α; psoriasis -- tumour necrosis factor antagonists -- side effects -- rheumatoid arthritis; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2005.037424
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Blockage of tumour necrosis factor α (TNFα) is highly effective in rheumatic diseases, especially in rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis. Furthermore, TNFα antagonists have also been shown to significantly reduce psoriatic skin lesions. Case reports: A series of nine patients with RA who were treated with different types of TNFα antagonists and who unexpectedly developed either a new onset or an exacerbation of psoriatic skin lesions are reported